Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients

Diabetes and Metabolism

Volumn 35, Issue 3, 2009, Pages 214-219

  Ezzidi, I ^a   Mtiraoui, N ^a   Chaieb, M ^b   Kacem, M ^b   Mahjoub, T ^a   Almawi, W Y ^c  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Diabetes; PCR; Plasminogen activator inhibitor 1; Polymorphism; Retinopathy

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NON PROLIFERATIVE RETINOPATHY; POLYMERASE CHAIN REACTION; PROLIFERATIVE RETINOPATHY; PROTECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; RISK FACTOR; TUNISIA;

ADULT; AGE OF ONSET; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TUNISIA;

EID: 67349163252     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2008.12.002     Document Type: Article

References (35)

1. Ciulla T.A., Amador A.G., and Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26 (2003) 2653-2664
2. Hallman D.M., Huber Jr. J.C., Gonzalez V.H., Klein B.E., Klein R., and Hanis C.L. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County Texas. Diabetes Care 28 (2005) 1163-1168
3. Uhlmann K., Kovacs P., Boettcher Y., Hammes H.P., and Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 114 (2006) 275-294
4. Erem C., Hacihasanoǧlu A., Celik S., Ovali E., Ersöz H.O., Ukinç K., et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 14 (2005) 22-30
5. Funk M., Endler G., Exner M., Marculescu R., Endler L., Abrahamian H., et al. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wochenschr 117 (2005) 707-710
6. Hudson B.I., Stickland M.H., Futers T.S., and Grant P.J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50 (2001) 1505-1511
7. Kashiwagi A., and Araki S. Relation between polymorphisms G1704T and G82S of RAGE gene and diabetic retinopathy in Japanese type 2 diabetic patients. Intern Med 44 (2005) 397-398
8. Kamiuchi K., Hasegawa G., Obayashi H., Kitamura A., Ishii M., Yano M., et al. Intercellular adhesion molecule-1 (ICAM-1) polymorphism is associated with diabetic retinopathy in Type 2 diabetes mellitus. Diabet Med 19 (2002) 371-376
9. Nagi D.K., McCormack L.J., Mohamed-Ali V., Yudkin J.S., Knowler W.C., and Grant P.J. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 20 (1997) 1304-1309
10. Santos K.G., Tschiedel B., Schneider J., Souto K., and Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 61 (2003) 133-136
11. Wang Y., Ng M.C., Lee S.C., So W.Y., Tong P.C., Cockram C.S., et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26 (2003) 2410-2415
12. Dobrovolsky A.B., and Titaeva E.V. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 67 (2002) 99-108
13. Sprengers E.D., and Kluft C. Plasminogen activator inhibitors. Blood 69 (1987) 381-387
14. Stegnar M., Uhrin P., Peternel P., Mavri A., Salobir-Pajnic B., Stare J., et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79 (1998) 975-979
15. Kathiresan S., Gabriel S.B., Yang Q., Lochner A.L., Larson M.G., Levy D., et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 112 (2005) 1728-1735
16. Grubic N., Stegnar M., Peternel P., Kaider A., and Binder B.R. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84 (1996) 431-443
17. Henry M., Chomiki N., Scarabin P.Y., Alessi M.C., Peiretti F., Arveiler D., et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17 (1997) 851-858
18. Gori A.M., Marcucci R., Fatini C., Gensini F., Sticchi E., Sodi A., et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 92 (2004) 54-60
19. Grant M.B., Ellis E.A., Caballero S., and Mames R.N. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. Exp Eye Res 63 (1996) 233-244
20. Festa A., D'Agostino Jr. R., Rich S.S., Jenny N.S., Tracy R.P., and Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 107 (2003) 2422-2427
21. Globocnik-Petrovic M., Hawlina M., Peterlin B., and Petrovic D. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Ophthalmologica 217 (2003) 219-224
22. Zietz B., Buechler C., Drobnik W., Herfarth H., Schölmerich J., and Schäffler A. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. Endocr Res 30 (2004) 443-453
23. Cundiff D.K., and Nigg C.R. Diet and diabetic retinopathy: insights from the diabetes control and complications trial (DCCT). MedGenMed 7 (2005) 3
24. Henricsson M., Nilsson A., Janzon L., and Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 14 (1997) 123-131
25. Stratton I.M., Cull C.A., Adler A.I., Matthews D.R., Neil H.A., and Holman R.R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49 (2006) 1761-1769
26. Rema M., Srivastava B.K., Anitha B., Deepa R., and Mohan V. Association of serum lipids with diabetic retinopathy in urban south Indians - The chennai urban rural epidemiology study (CURES) Eye Study-2. Diabet Med 23 (2006) 1029-1036
27. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
28. Margaglione M., Cappucci G., d'Addedda M., Colaizzo D., Giuliani N., Vecchione G., et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 18 (1998) 562-567
29. Eriksson P., Kallin B., van 't Hooft F.M., Båvenholm P., and Hamsten A. Allele-specific in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92 (1995) 1851-1855
30. Brignole F., Baudouin C., Roul C., Gastaud P., and Bayle J. Tissue-type plasminogen activator (TPA) and plasminogen activator inhibitor (PAI-1) in serum, vitreous and subretinal fluid from patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 35 (1994) S2041
31. Grant M.B., Spoerri P.E., Player D.W., Bush D.M., Ellis E.A., Caballero S., et al. Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci 41 (2000) 2296-2302
32. Nguyen T.T., and Wong T.Y. Retinal vascular manifestations of metabolic disorders. Trends Endocrinol Metab 17 (2006) 262-268
33. Lambert V., Munaut C., Noël A., Frankenne F., Bajou K., Gerard R., et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15 (2001) 1021-1027
34. Mali R.S., Cheng M., and Chintala S.K. Plasminogen activators promote excitotoxicity-induced retinal damage. FASEB J 19 (2005) 1280-1289
35. Buchbinder S., Rudofsky Jr. G., Humpert P.M., Schilling T., Zorn M., Bierhaus A., et al. The DG10S478 variant in the TCF7L2 gene is not associated with microvascular complications in type 2 diabetes. Exp Clin Endocrinol Diabetes 116 (2008 Apr) 211-214